34 Stocks Moving In Friday’s Mid-Day Session
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08.
Paratek To Present New Data For NUZYRA At IDWeek 2021 Wednesday, Sept. 29
Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infections
BOSTON,
How Good Are Paratek Pharmaceuticals’s Earnings? | Return On Capital Employed
According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also posted a total of $57.49 million in sales, a 249.98% increase since Q1.
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Paratek’s Antibiotic Gets FDA Orphan Drug Tag For Lung Infection
The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc’s (NASDAQ:PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous Mycobacteria (NTM). The…
Paratek Pharmaceuticals Granted Orphan Drug Designation For Treatment Of Infections Caused By Nontuberculous Mycobacteria
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=741020
Paratek Pharmaceuticals: Q2 Earnings Insights
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 137.74% over the past year to $0.20, which missed the estimate of $0.31.
Paratek Pharmaceuticals Q2 EPS $0.20 Misses $0.31 Estimate, Sales $57.49M Miss $60.99M Estimate
Paratek Pharmaceuticals (NASDAQ:PRTK) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.31 by 35.48 percent. This is a 137.74 percent increase over losses of $(0.53) per
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.